Skip to main content
Clinical Trials/NCT02157662
NCT02157662
Completed
N/A

Coronary Atherosclerosis in Outlier Subjects: Protective and Individual Risk Factor Evaluation

Gruppo di Ricerca GISSI10 sites in 2 countries544 target enrollmentJanuary 2011
ConditionsAtherosclerosis

Overview

Phase
N/A
Intervention
Not specified
Conditions
Atherosclerosis
Sponsor
Gruppo di Ricerca GISSI
Enrollment
544
Locations
10
Primary Endpoint
Number of patients in each Group with a cardiovascular Event
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The risk of developing clinical manifestations of ischemic heart disease is currently assessed by using integrated multifactorial prediction models based on the presence of non-modifiable risk factors, such as age, gender and a family history of early ischemic heart disease along with risk factors which are defined as conventional, such as arterial hypertension, hypercholesterolemia, cigarette smoking and diabetes mellitus.

However, if the relationship between risk factors and ischemic heart disease clinical manifestations shows some limitations, the relation between risk factors and the coronary atherosclerosis process underlying most ischemic syndromes seems to be even weaker.

In fact there is significant individual variability and the limits of such relationship are demonstrated by a non negligible number of subjects at the outliers of mean behaviour of the prediction model. At one outlier, in the presence of multiple risk factors, these subjects do not develop neither coronary events nor coronary atherosclerosis whereas, at the other, coronary events and disease occur in the absence of risk factors.This study aims at detecting new protection and susceptibility factors, thus enabling to formulate new etiopathogenetic hypotheses concerning coronary atherosclerosis and to identify new therapeutic targets.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
September 13, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Gruppo di Ricerca GISSI
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Group A: subjects with total absence of coronary atherosclerosis and 3 or more risk factors (reported by the subject or documented at the MDCT)
  • Group B: subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
  • Using the same criteria, two control populations will be selected, with a case:control 1:1 ratio, consisting in:
  • Group C: subjects with total absence of coronary atherosclerosis and 0-1 risk factor (reported by the subject or documented at the MDCT)
  • Group D: subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.

Exclusion Criteria

  • common contraindications to MDCT (chronic renal failure with serum creatinine \> 2.0 mg/dl, suspected pregnancy, arrhythmias, body mass index \> 40, allergy to iodized contrast agent).
  • previous cardiovascular events (heart failure, acute myocardial infarction, unstable angina, chronic stable angina, previous percutaneous or surgery coronary revascularization) both clinically evident and found by conventional diagnostic methods previous performed.
  • subjects which MDCT does not meet the quality control criteria defined below in the protocol.
  • patients with previous documented or identified at the moment of MDCT such as dilated cardiomyopathy regardless of etiology, obstructive hypertrophic cardiomyopathy, atrial fibrillation, myocarditis and inflammatory vascular disease.

Outcomes

Primary Outcomes

Number of patients in each Group with a cardiovascular Event

Time Frame: 5 years

Secondary Outcomes

  • Polymorphisms associated with chromosome 9 in each patient(At enrollment visit)

Study Sites (10)

Loading locations...

Similar Trials